Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 13Non-Muscle Invasive Bladder Neoplasms 7Side Effect of Drug 1Sarcoma 1Osteosarcoma 1Oligospermia 1Neuroblastoma 1Neoplasms 1Melanoma 1Fibrosis 1Carcinoma, Transitional Cell 1

Interventions

pembrolizumab 37Gemcitabine 29Nivolumab 20Cisplatin 19atezolizumab 15avelumab 14Docetaxel 13enfortumab vedotin 10Carboplatin 10durvalumab 9Magnetic Resonance Spectroscopy 9Ipilimumab 8Paclitaxel 7Pemetrexed 6toripalimab 5cabozantinib 5Fluorodeoxyglucose F18 5sacituzumab govitecan 4cabazitaxel 4Taxes 4vinflunine 3tremelimumab 3pemigatinib 3X-Rays 3Standard of Care 3Specimen Handling 3Radiotherapy 3Mitomycin 3Immunotherapy 3Immunoglobulin G 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Carcinoma, Transitional Cell × BCG Vaccine × Clear all
NCT00070070 2022-10-12

Vaccine Therapy in Treating Patients With Transitional Cell Carcinomas

Ludwig Institute for Cancer Research

Phase 1 Completed
6 enrolled 7 charts
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡